304 related articles for article (PubMed ID: 16556178)
1. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
2. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
3. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
4. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
5. The suppression of gastro-oesophageal reflux by alginates.
Dettmar PW; Hampson FC; Taubel J; Lorch U; Johnstone LM; Sykes J; Berry PJ
Int J Clin Pract; 2007 Oct; 61(10):1654-62. PubMed ID: 17681004
[TBL] [Abstract][Full Text] [Related]
6. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
7. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers.
Hürlimann S; Michel K; Inauen W; Halter F
Am J Gastroenterol; 1996 Jun; 91(6):1173-80. PubMed ID: 8651166
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants.
Corvaglia L; Aceti A; Mariani E; De Giorgi M; Capretti MG; Faldella G
Aliment Pharmacol Ther; 2011 Feb; 33(4):466-70. PubMed ID: 21158879
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
Drug Dev Ind Pharm; 2018 Jan; 44(1):30-39. PubMed ID: 28836872
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
12. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
[TBL] [Abstract][Full Text] [Related]
13. [Estimation of efficiency of alginate-raft barrier in treatment of gastroesophageal reflux disease].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2008; (6):77-81. PubMed ID: 19334430
[No Abstract] [Full Text] [Related]
14. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry.
Zentilin P; Dulbecco P; Savarino E; Parodi A; Iiritano E; Bilardi C; Reglioni S; Vigneri S; Savarino V
Aliment Pharmacol Ther; 2005 Jan; 21(1):29-34. PubMed ID: 15644042
[TBL] [Abstract][Full Text] [Related]
15. In-vivo anti-reflux and raft properties of alginates.
Lambert JR; Korman MG; Nicholson L; Chan JG
Aliment Pharmacol Ther; 1990 Dec; 4(6):615-22. PubMed ID: 2129648
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
17. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
Kwiatek MA; Roman S; Fareeduddin A; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2011 Jul; 34(1):59-66. PubMed ID: 21535446
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial.
Sulz MC; Manz M; Grob P; Meier R; Drewe J; Beglinger C
Digestion; 2007; 75(2-3):69-73. PubMed ID: 17496418
[TBL] [Abstract][Full Text] [Related]
19. [Alginate-raft preparations in the treatment of acid reflux and heartburn (literature review)].
Mandel KG; Deggi BP; Brodi DA; Jeykobi GI
Eksp Klin Gastroenterol; 2008; (4):64-77. PubMed ID: 19145905
[No Abstract] [Full Text] [Related]
20. [Treatment with sodium alginate of gastroesophageal reflux disease in childhood: efficacy and tolerance assessment].
Maestri L
Pediatr Med Chir; 2001; 23(3-4):187-9. PubMed ID: 11723856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
